Furthermore, the sterol O-acyltransferase 1 (SOAT1) inhibitor Avasimibe disrupts lipid metabolism by reducing cholesterol ester synthesis, impairing lymphangiogenesis, and inhibiting tumor proliferation through downregulation of SREBP1/2 and VEGF-C [107]. This evidence concerns the gene SREBF1 and neoplasm.